Chemical structure of molecule BIIB091 Biogen reversible BTK kinase inhibitor

oral reversible BTK kinase inhibitor

Ph. I candidate for multiple sclerosis

from prior BTK inhibitor BIIB0685

Journal of Medicinal Chemistry


5.      The Biogen reversible BTK kinase inhibitor, BIIB091, is a highly selective, phase I clinical candidate for multiple sclerosis. Irreversible BTK inhibitors have been explored and developed extensively, primarily in…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.